GlassScriptPhysician profile
Charles D Mcmahon
NPI 1639168735
$46,688.10
in general payments reported to CMS, 2019-2025
9 companies · $46K in 2025
The $46K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $67.72 · 2021: $136 · 2022: $62.08 · 2024: $43.52 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $81.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,052.29 |
| Food and Beverage | $81.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $46,052.29 | 2025 | |
| Aerie Pharmaceuticals, INC. | $289.65 | 2019-2021 | |
| Hoffmann-La Roche Limited | $140.40 | 2019 | |
| Thea Pharma INC. | $76.04 | 2022-2024 | Iyuzeh |
| Abbvie INC. | $44.05 | 2024-2025 | |
| Lumibird Medical INC. | $28.61 | 2020 | |
| Bausch & Lomb Americas INC. | $23.30 | 2025 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $20.66 | 2019 | |
| Akorn, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.